UCB (OTCMKTS:UCBJF) Sets New 12-Month High - Time to Buy?

Key Points

• UCB SA shares reached a new 52-week high of $218.19 during trading, closing at the same price after previously being at $211.99.
• Morgan Stanley has upgraded UCB to an "overweight" rating, indicating a positive outlook on the company's stock.
• The company's primary products include treatments for neurological and immunological diseases, highlighting its focus on biopharmaceuticals in critical health areas.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $218.19 and last traded at $218.19, with a volume of 26 shares changing hands. The stock had previously closed at $211.99.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of UCB to an "overweight" rating in a report on Monday, June 23rd.

UCB Trading Up 2.9%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The stock has a fifty day moving average price of $193.49 and a 200-day moving average price of $183.64.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.